Evaluation of Effect of Stopping Mass Azithromycin Treatment after five years
Not Applicable
Recruiting
- Conditions
- Eye DiseasesTrachoma
- Registration Number
- PACTR201211000437277
- Lead Sponsor
- The Carter Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
All districts in West Amhara that have completed five or more annual rounds of MDA with azithromycin and have been surveyed for impact will be eligible for inclusion into the study.
Exclusion Criteria
Districts where SAFE has been implemented for less than 5 years or where impact evaluations have showed prevalence of TF in children 1-9 years to be below 10% will not be included into the study. In the excluded districts, the SAFE strategy will be continued as per the WHO standards and national guidelines.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of TF (trachomatous inflammation-follicular) in children ages 1-9 years;¿Prevalence of ocular Chlamydia infection in children aged 1-9 years;¿Prevalence of TS in people aged 15 years and abov
- Secondary Outcome Measures
Name Time Method ¿Prevalence of TI in children aged 1-9 years;¿Prevalence of clean faces in children aged 1-9 years;¿Prevalence of TS in people aged below 15 years;¿Uptake of SAFE interventions at the individual and household level